Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul-Aug;100(4):501129.
doi: 10.1016/j.abd.2025.501129. Epub 2025 Jun 18.

Influence of sentinel lymph node biopsy on the prognosis of acral melanoma patients

Affiliations

Influence of sentinel lymph node biopsy on the prognosis of acral melanoma patients

Thiago Francischetto et al. An Bras Dermatol. 2025 Jul-Aug.

Abstract

Background: Sentinel lymph node (SLN) biopsy in melanoma patients has an important role in staging, prognosis assessment, and treatment definition. Few studies have evaluated its role in the Acral Melanoma (AM) subtype.

Objective: To evaluate the results of SLN biopsy in 79 patients with acral melanoma treated at a single oncological center and compare them with the data described in the literature.

Methods: Between January 2016 and December 2022, the authors analyzed all patients with AM who underwent SLN biopsy in a single institute. The authors analyzed the epidemiological, clinical and histopathological data. Overall Survival (OS) and Disease-Free Survival (DFS) curves were estimated using the Kaplan-Meier method. Multivariate analyses were conducted using the Cox regression model.

Results: During the period, the authors analyzed 79 cases. The mean age was 60 years and median thickness was 4.5 mm and 67.1% had ulceration. SLN was positive in 27 patients (34.2%). The estimated OS and DFS were 67.7% and 45.2%. OS was better in the negative SLN group compared to the positive SLN group (70.9% vs. 53.2%), but without statistical significance (p = 0.08). Estimated DFS for positive SLN was associated with a significantly worse prognosis (33.8 × 46.7%, p = 0.001).

Study limitations: The retrospective nature of the study and the limited number of patients.

Conclusions: The present study has significant implications for determining prognosis. Patients with AM and positive SLN had a worst prognosis compared to those with negative SLN.

Keywords: Biopsy; Melanoma; Prognosis; Sentinel lymph node.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None declared.

Figures

Figure 1
Figure 1
Kaplan-Meier overall survival curves for acral melanoma submitted a sentinel lymph node biopsy.
Figure 2
Figure 2
Kaplan-Meier disease free survival curves for acral melanoma submitted a sentinel lymph node biopsy.
Figure 3
Figure 3
Kaplan-Meier overall survival curves for acral melanoma submitted a sentinel lymph node biopsy by status of sentinel lymph node.
Figure 4
Figure 4
Kaplan-Meier overall survival curves for acral melanoma submitted a sentinel lymph node biopsy by Breslow < 2 mm versus ≥ 2 mm.
Figure 5
Figure 5
Kaplan-Meier overall survival curves for acral melanoma submitted a sentinel lymph node biopsy by ulceration.
Figure 6
Figure 6
Kaplan-Meier overall survival curves for acral melanoma with positive sentinel lymph node by treatment employed.
Figure 7
Figure 7
Kaplan-Meier disease free survival curves for acral melanoma submitted a sentinel lymph node biopsy by status of sentinel lymph node.
Figure 8
Figure 8
Kaplan-Meier disease free survival curves for acral melanoma submitted a sentinel lymph node biopsy by Breslow < 2 mm versus ≥ 2 mm.
Figure 9
Figure 9
Kaplan-Meier disease free survival curves for acral melanoma submitted a sentinel lymph node biopsy by ulceration.
Figure 10
Figure 10
Kaplan-Meier disease free survival curves for acral melanoma with positive sentinel lymph node by treatment employed.

Similar articles

References

    1. Pollack L.A., Li J., Berkowitz Z., Weir H.K., Wu X.C., Ajani U.A., et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol. 2011;65:S78–86. - PMC - PubMed
    1. Zell J.A., Cinar P., Mobasher M., Ziogas A., Meyskens F.L., Jr, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008;26:66–75. - PubMed
    1. Bradford P.T., Goldstein A.M., McMaster M.L., Tucker M.A. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145:427–434. - PMC - PubMed
    1. Shaikh W.R., Dusza S.W., Weinstock M.A., Oliveria S.A., Geller A.C., Halpern A.C. Melanoma thickness and survival trends in the United States, 1989-2009. J Natl Cancer Inst. 2015;108 - PMC - PubMed
    1. Goydos J.S., Shoen S.L. Acral lentiginous melanoma. Cancer Treat Res. 2016;167:321–329. - PubMed

LinkOut - more resources